β2-Агонисты короткого действия: особенности применения при хронических обструктивных заболеваниях легких
β2-Агонисты короткого действия: особенности применения при хронических обструктивных заболеваниях легких
Княжеская Н.П., Динер Н.Е. β2-Агонисты короткого действия: особенности применения при хронических обструктивных заболеваниях легких. Consilium Medicum. 2008; 10 (10): 41–45.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Авдеев С.Н. Устройства доставки ингаляционных препаратов, используемые при терапии заболеваний дыхательных путей. Рус. мед. журн. 2002; 10 (5): 255–26.
2. Бронхиальная астма. Глобальная стратегия: совместный доклад Национального института Сердце, Легкие, Кровь и Всемирной организации здравоохранения. М.: Атмосфера, 2002.
3. Цой А.Н., Архипов В.В. Вопросы клинической фармакологии b2-адреностимуляторов. Рус. мед. журн. 2001; 9 (21): 930–3.
4. Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: Evidence based guidelines: American College of Chest Physicians/American Collegeof Asthma, Allergy, and Immunology. Chest 2005; 127: 335–71.
5. Fink JB, Rubin BK. Problems with Inhaler Use: a Call for improved Clinican and Patient Education. Respir Care 2005; 50 (10): 1360–74.
6. Hall Ian P. b2-Adrenoreceptor agonists. In: Barnes P.J.: Asthma and COPD Basic Mechanisms and Clinical Management, 1st ed., CopyrightC 2002, Academic Press.
7. June D. Achieving to change: challenges and successes in the formulation of CFC-free MDIs. Eur Respir Rev 1997; 7 (41): 32–4.
8. Lenney J, Inns JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation device. Respir Med 2000; 94: 496–500.
9. Liggett SB. Polymorphisms of the β2–adrenergic receptor in asthma. Am J Respir Cri Care Med 1997; 156: 156–62.
10. Lipworth BJ, Hall IP, Tan S et al. Effects of genetic polymorphism on ex vivo and in vivo function of β2–adrenoceptors in asthmatic patients. Chest 1999; 115: 324–8.
11. Lipworth BJ, Kopelman GH, Wheatley AP et al. β2-Adrenoceptor promoter polymorphism: extended halotypes and functional effects in peripheral blood mononuclear cells. Thorax 2002; 57: 61–6.
12. Matthys H. CFCs and their effect on the ozone layer: the Montreal Protocol and consequences for physicians. Eur Respir Rev 1997; 7 (41): 29–31
13. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the asthma insights and reality in Europe (AIRE) study. Eur Respir J 2000; 16: 802–7.
14. Rabe KF, Adachi M, Lai CK et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004; 114: 40–7.
15. Rau GL. Practical Problems with Aerosol Therapy in COPD. Respir Care 2006; 51 (2): 158–72.
16. Rubin BK, Fink JB. Optimizing Aerosol Delivery by Pressurized Metered-Dose Inhalers. Respir Care2005; 50 (9): 1191–7.
2. Бронхиальная астма. Глобальная стратегия: совместный доклад Национального института Сердце, Легкие, Кровь и Всемирной организации здравоохранения. М.: Атмосфера, 2002.
3. Цой А.Н., Архипов В.В. Вопросы клинической фармакологии b2-адреностимуляторов. Рус. мед. журн. 2001; 9 (21): 930–3.
4. Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: Evidence based guidelines: American College of Chest Physicians/American Collegeof Asthma, Allergy, and Immunology. Chest 2005; 127: 335–71.
5. Fink JB, Rubin BK. Problems with Inhaler Use: a Call for improved Clinican and Patient Education. Respir Care 2005; 50 (10): 1360–74.
6. Hall Ian P. b2-Adrenoreceptor agonists. In: Barnes P.J.: Asthma and COPD Basic Mechanisms and Clinical Management, 1st ed., CopyrightC 2002, Academic Press.
7. June D. Achieving to change: challenges and successes in the formulation of CFC-free MDIs. Eur Respir Rev 1997; 7 (41): 32–4.
8. Lenney J, Inns JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation device. Respir Med 2000; 94: 496–500.
9. Liggett SB. Polymorphisms of the β2–adrenergic receptor in asthma. Am J Respir Cri Care Med 1997; 156: 156–62.
10. Lipworth BJ, Hall IP, Tan S et al. Effects of genetic polymorphism on ex vivo and in vivo function of β2–adrenoceptors in asthmatic patients. Chest 1999; 115: 324–8.
11. Lipworth BJ, Kopelman GH, Wheatley AP et al. β2-Adrenoceptor promoter polymorphism: extended halotypes and functional effects in peripheral blood mononuclear cells. Thorax 2002; 57: 61–6.
12. Matthys H. CFCs and their effect on the ozone layer: the Montreal Protocol and consequences for physicians. Eur Respir Rev 1997; 7 (41): 29–31
13. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the asthma insights and reality in Europe (AIRE) study. Eur Respir J 2000; 16: 802–7.
14. Rabe KF, Adachi M, Lai CK et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004; 114: 40–7.
15. Rau GL. Practical Problems with Aerosol Therapy in COPD. Respir Care 2006; 51 (2): 158–72.
16. Rubin BK, Fink JB. Optimizing Aerosol Delivery by Pressurized Metered-Dose Inhalers. Respir Care2005; 50 (9): 1191–7.
Авторы
Н.П.Княжеская, Н.Е.Динер
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.